XAll Individual Users: You may have noticed, we have just launched our new website. We will be adding more features over the upcoming weeks that you will like, so there may be a few hiccups along the way. If this is your first time visiting since our relaunch, please reset your password so you can still access our journals and CME activities that we have been providing for over 80 years. If you have any questions or comments please contact us at webadmin@psychiatrist.com.
XAll Individual Users: You may have noticed, we have just launched our new website. We will be adding more features over the upcoming weeks that you will like, so there may be a few hiccups along the way. If this is your first time visiting since our relaunch, please reset your password so you can still access our journals and CME activities that we have been providing for over 80 years. If you have any questions or comments please contact us at webadmin@psychiatrist.com.
Certain antipsychotics are known to increase weight and the risk for diabetes. Could some medications for diabetes promote not only glycemic control but also weight loss in patients taking antipsychotics? In this CME activity, review the results of a small retrospective study.
What steps do you take when patients exhibit tardive dyskinesia? Are you familiar with treatment guidelines and data on approved and non-approved strategies? Explore recommendations from Dr Daniel Kremens.
Photophobia was once considered a rapidly reversible adverse effect of lithium mainly occurring in younger patients. This case describes a 50-year-old woman who experienced delayed-recovery lithium-induced photophobia and eye irritation with lithium.
Two medications are FDA-approved to treat tardive dyskinesia, and new long-term evidence has been reported. Follow along as expert Joseph P. McEvoy, MD, reviews the evidence.
Levetiracetam is often prescribed by neurologists. This report sheds light on the psychiatric sequelae associated with levetiracetam while highlighting clinical correlates and management issues.
Vitamin B12 deficiency is associated with various psychiatric symptoms. This study assessed the pattern of serum folate and vitamin B12 levels in psychiatric inpatients compared to nonpsychiatric controls in India.
Adjunctive atypical antipsychotics can increase antidepressant response in depressed patients, but may cause adverse metabolic effects. This study examines the metabolic effects of adjunctive brexpiprazole in patients with major depressive disorder.
Abnormal thyroid hormone levels are among the most common nonpsychiatric causes of mood and anxiety symptoms. This retrospective study examines the extent of the issue in youth with mood and anxiety disorders and suggests a need for targeted screening.
Can lurasidone induce mania? Read about a patient who presented in a depressive episode with psychotic features who became acutely manic after starting lurasidone monotherapy.
Most agree that a "healthy diet" confers health benefits, but defining "healthy" foods and specific benefits is increasingly confusing. This ASCP Corner article considers the evidence base for dietary interventions purported to have psychopharmacologic properties.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”